All the latest news and updates about GLP-1 Drugs
The two simultaneous Incyte trials in HS saw more than 40% of patients on povorcitinib achieving a clinical response.
Your email address will not be published. Required fields are marked *
Comment *
Name *
Email *
Website
Save my name, email, and website in this browser for the next time I comment.